4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
Earnings & Valuation
This table compares 4D Molecular Therapeutics and TransCode Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 4D Molecular Therapeutics | $85.21 million | 5.58 | -$140.11 million | ($2.42) | -3.85 |
| TransCode Therapeutics | N/A | N/A | -$16.75 million | ($27.24) | -0.32 |
Analyst Ratings
This is a breakdown of current recommendations for 4D Molecular Therapeutics and TransCode Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 4D Molecular Therapeutics | 1 | 1 | 8 | 0 | 2.70 |
| TransCode Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
4D Molecular Therapeutics currently has a consensus target price of $31.25, indicating a potential upside of 235.66%. TransCode Therapeutics has a consensus target price of $280.00, indicating a potential upside of 3,152.03%. Given TransCode Therapeutics’ higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than 4D Molecular Therapeutics.
Insider and Institutional Ownership
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 0.0% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
4D Molecular Therapeutics has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
Profitability
This table compares 4D Molecular Therapeutics and TransCode Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 4D Molecular Therapeutics | -164.43% | -31.75% | -28.30% |
| TransCode Therapeutics | N/A | -440.64% | -205.50% |
Summary
4D Molecular Therapeutics beats TransCode Therapeutics on 9 of the 12 factors compared between the two stocks.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
About TransCode Therapeutics
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
